Sanofi took the opportunity at the 55th annual European Association for the Study of Diabetes to present new data from the first randomised control study directly comparing its Toujeo product with insulin degludec (iDeg) in patients starting treatment with insulin for the first time to manage their type 2 diabetes.
In adult patients with type 2 diabetes and moderate-to-severe kidney impairment, the results of the study showed that Toujeo produced a 0.43% greater reduction in average blood sugar in patients with moderate-to-severe renal impairment throughout the 24-week s
